Leerink Partners maintained an Outperform rating on Arvinas Inc. (NASDAQ:ARVN) but reduced the price target from $62.00 to ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

Limited to estrogen receptor-positive breast cancer (ER+) the compound addresses many common concerns with existing treatment ...

After a second breast cancer diagnosis at 61, I faced 17 rounds of chemo, surgery and radiation, changing my perspective on life and leading to a new normal.

More testing is needed, but if the same results are seen in humans, it could transform treatment of the disease.

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...

Despite significant therapeutic advances, breast cancer remains a leading cause of cancer-related death in women.

Analyst Derek Archila from Wells Fargo maintained a Hold rating on Zentalis Pharmaceuticals (ZNTL – Research Report) and decreased the price ...

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...